Schroder Adveq
VC Fund
Zürich, Switzerland
Schroder Adveq is a leading asset manager investing in private equity globally.
- Total investments:
- 36
- Last investment:
- Lead investor:
- 11%
- Fund size:
- $113M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Schroder Adveq invests in
Stages Schroder Adveq invests in
Countries Schroder Adveq invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $5.6M–$23M
- Series B
- $11M–$73M
- Series C
- $15M–$100M
Investment Focus
Industry
- Biotechnology 14 (39%)
- Health Care 12 (33%)
- Therapeutics 11 (31%)
- Medical 3 (8%)
- Life Science 3 (8%)
Stage
- Series B 10 (28%)
- Series C 8 (22%)
- Series A 5 (14%)
- Seed 2 (6%)
- Funding Round 2 (6%)
Country
- Switzerland 8 (22%)
- United States 7 (19%)
- India 3 (8%)
- United Kingdom 2 (6%)
- China 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Benjamin Alt
Head of Investments DACH, Nordics & CEE
|
Head of Investments DACH, Nordics & CEE | Total investments: 0 | Find email | |
Rainer Ender
Head of Investment Management
|
Head of Investment Management | Total investments: 0 | Find email | |
Viswanathan Parameswar
Asset Management - Global Private Equity
|
Asset Management - Global Private Equity | Total investments: 0 | Find email | |
Bruno E. Raschle
Founder
|
Founder | Total investments: 1 | Find email | |
|
Brun Raschle
Managing director
|
Managing director | Total investments: 7 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Memo Therapeutics
|
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $22M / Series C / May 07, 2024 | |
Bizongo
|
Bizongo develops a tech-enabled B2B e-commerce and supply chain platform for packaging, apparel, and other customized goods. It digitally transforms the fragmented and unorganized yet unique and ubiquitous B2B segment of customized goods. The company focuses on packaging, textiles, apparel, and other contract manufacturing goods as its productportfolio and has a network of over 1500 curated manufacturers across these categories.Bizongo was founded in 2015 by three IIT graduates Aniket Deb, Sachin Agrawal, and Ankit Tomar. | $50M / Series E / Oct 04, 2023 | |
Lenskart
|
Lenskart, the first of its kind online optical store in India, has made it possible to acquire a good quality pair of specs with prescription lenses for just Rs. 399. With a 48-hour free home delivery guarantee and 365 days return policy, Lenskart.com is doing what e-commerce hasn’t been able to do in India yet.The website has over 500 designs ofeye frames, in multiple colors, for all age groups, from Rs. 399 all the way to Rs. 4,000 for a pair. All one needs to do is select a frame, fill in their power, and place an order. You can pay online or at the time of delivery.Lenskart.com has the biggest collection of discounted contact lenses consisting of all top-notch brands (viz. Johnson & Johnson, Bausch & Lomb, Ciba Vision to name a few) and be it disposable, toric, colored, or bifocal contact lenses, you can find all possible types here. Lenskart is dedicated to providing its customers with a simple, hassle-free way to replace their contact lenses. One can receive the exact same contact lens, their doctor prescribed, delivered to their door, at a great price. | $28.3M / Series I / Jun 09, 2022 | |
ImmunOs Therapeutics
|
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease. | $72.9M / Series B / Jun 07, 2022 | |
HAYA Therapeutics
|
HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $5M / Seed / Feb 09, 2022 | |
LEAP India
|
LEAP INDIA is a leading pallet and container rental provider across India began its embarking journey in 2013. Ranging from strategic management, lumber sourcing, distribution & channel marketing, sales & supply chain, LEAP’s business is of returnable packaging and pooling of equipments namely; wooden pallets & boxes, plasticcontainers, metal wire mesh catering to all sectors that work with these products to store or transfer goods from one site to another. LEAP’s efforts are focused to support its customers right where they are. Our competence lies in management of assets and inventory and we look out for logistic challenges to support them with smart solutions. We provide end to end solutions to our clientele for the movement of products. By defining high standard of products and services, we streamline national and multi-national operational tasks for our customers. | $34M / Secondary Market / Aug 04, 2021 | |
Alentis Therapeutics
|
Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases. | $66.8M / Series B / Jun 15, 2021 | |
Tessian
|
Tessian’s mission is to secure the human layer. Using machine learning technology, Tessian automatically stops data breaches and security threats caused by human error - like data exfiltration, accidental data loss, business email compromise, and phishing attacks - with minimal disruption to employees' workflow. As a result, employees areempowered to do their best work, without security getting in their way. Founded in 2013, Tessian is backed by renowned investors like Sequoia, Accel, March Capital, and Balderton, and has offices in San Francisco and London. | $65M / Series C / May 25, 2021 | |
|
HAYA Therapeutics
|
HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $20.1M / Seed / May 20, 2021 | |
|
HAYA Therapeutics
|
HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $18M / Seed / May 05, 2021 | |
| See all 36 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Schroder Adveq invest in?
Schroder Adveq invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 36 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Schroder Adveq's check size?
Schroder Adveq typically joins rounds of $5.6M–$23M at Series A, $11M–$73M at Series B and $15M–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Schroder Adveq participates in.
How do I contact Schroder Adveq?
Public channels for Schroder Adveq include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Schroder Adveq?
The team at Schroder Adveq includes Benjamin Alt (Head of Investments DACH, Nordics & CEE), Rainer Ender (Head of Investment Management) and Viswanathan Parameswar (Asset Management - Global Private Equity), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
